 |
W2O handles media for MyoKardia as the clinical biopharmaceutical firm agrees to be acquired by Bristol-Myers-Squibb for $13.1B in cash, which represents a 60 percent premium over the California-based company’s Oct. 2 closing stock price.
BMS CEO Giovanni Caforio said MyKardia’s mavacamten cardiovascular drug was a key reason for the deal.
He called mavacamten, “a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease.”
Mavacamten treats obstructive hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes too thick.
There are 160K to 200K people in the US and EU diagnosed with HCM, which has no effective treatment. It’s estimated that only 25 percent of people with HCM receive a diagnosis.
MyoKardia expects to file a new drug application for mavacamten with the Food & Drug Administration during the first quarter of 2021.
W2O’s Julie Nomert handles MyoKardia, while Hannah Deresiewicz of Stern Investor Relations handles Wall Street.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
